Veit-Haibach, Patrick
Ahlström, Håkan
Boellaard, Ronald
Delgado Bolton, Roberto C.
Hesse, Swen
Hope, Thomas
Huellner, Martin W.
Iagaru, Andrei
Johnson, Geoffrey B.
Kjaer, Andreas
Law, Ian
Metser, Ur
Quick, Harald H.
Sattler, Bernhard
Umutlu, Lale
Zaharchuk, Greg
Herrmann, Ken http://orcid.org/0000-0002-9662-7259
Funding for this research was provided by:
Universitätsklinikum Essen
Article History
Received: 30 June 2023
Accepted: 16 August 2023
First Online: 25 August 2023
Declarations
:
: This is a guideline and does not contain any studies with human participants performed by any of the authors.
: Author PVH has IIS grants from: Bayer Switzerland, Roche Pharmaceuticals, Siemens Healthineers, GE Healthcare and Point Biopharma. Author PVH has an Industry Sponsored Theranostic Trial: AAA. Author PVH has speaker fees and travel support from Siemens Healthineers and GE Healthcare. Author PVH has speaker fees from: Ontario Association of Radiologists and JCA PET/CT course. Author PVH receives editor fee from Springer Nature and reviewer compensation from Wellcome Trust. Author PVH receives strategic panel advisory compensation and travel support from the German Cancer Center. Author HA is co-founder and part-time employee of Antaros Medical AB, Mölndal, Sweden. He also owns stocks in Antaros Medical. Author SH received speaker honoraria from GE Healthcare and HERMES Medical Solutions. There are no other conflicts of interest with regard to the work in the manuscript. Author TH has grant funding to the institution from Clovis Oncology, Philips, GE Healthcare, Lantheus, Janssen, the Prostate Cancer Foundation, and the National Cancer Institute (R01CA235741 and R01CA212148). He received personal fees from Ipsen, Bayer and BlueEarth Diagnostics, and received fees from and has an equity interest in RayzeBio and Curium. Author MWH received grants and speaker honoraria from GE Healthcare, a fund by the Alfred and Annemarie von Sick legacy and a grant from the clinical research priority program (CRPP) Artificial Intelligence in Oncological Imaging Network of the University of Zurich. Author AI is an unpaid consultant to GE Healthcare and Lantheus, paid consultant to Amgen, IRE, Curium (EU), ITM, Novartis, Rayzebio and Telix, and a member of the scientific advisory board at Clarity Pharmaceuticals and Alpha9 Theranostics. Mayo Clinic receives funding from Novartis, Pfizer, MedTrace, Clarity, Clovis, and ViewPoint/Perspective for research conducted by author GBJ. Mayo Clinic receives funding for consulting with Pfizer, Novartis, Curium, Blue Earth, AstraZeneca and Lantheus conducted by author GBJ. Companies founded by author GBJ include Nucleus RadioPharma and The Green Clinic. Mayo Clinic and author GBJ hold patents pending on radionuclide theragnostic technologies. Author UM is a consultant for POINT Biopharma inc. Author HHQ has received research grants from Siemens Healthcare GmbH, Erlangen. Author BS has received speaker honoraria from SIEMENS Healthineers and is a member of the policy and regulatory affairs committee of EANM. Author GZ has received research grants from GE Healthcare and Bayer, consulting fees from Biogen, and equity in Subtle Medical, Inc. Author KH reports personal fees from: Bayer, SIRTEX, Adacap, Curium, Endocyte, IPSEN, Siemens Heatlhineers, GE Healthcare, Amgen, Fusion, Immedica, Onkowissen.de, Novartis, Molecular Partners, ymabs, Aktis Oncology, Theragnostics, Pharma15, Debiopharma, AstraZeneca and Janssen. Author KH also has personal fees and other from Sofie Biosciences, non-financial support from ABX and grants and personal fees from BTG. Authors RB, RCDB, AK, IA, and LU declared no conflict of interest.
: This guideline summarizes the views of the EANM Oncology-Theranostic Committee, SNMMI and ISMRM. It reflects recommendations for which the EANM, SNMMI and ISMRM cannot be held responsible. The recommendations should be taken into context of good practice of nuclear medicine and do not substitute for national and international legal or regulatory provisions.